These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3618626)

  • 21. Bile acid sequestrants.
    Ast M; Frishman WH
    J Clin Pharmacol; 1990 Feb; 30(2):99-106. PubMed ID: 2179278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bile acid sequestrants and hyperlipidaemia.
    Lancet; 1988 Jan; 1(8579):220-1. PubMed ID: 2893044
    [No Abstract]   [Full Text] [Related]  

  • 23. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia.
    Superko HR; Greenland P; Manchester RA; Andreadis NA; Schectman G; West NH; Hunninghake D; Haskell WL; Probstfield JL
    Am J Cardiol; 1992 Jul; 70(2):135-40. PubMed ID: 1626496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colestipol in familial type II hyperlipoproteinemia: a three-year trial.
    Harvengt C; Desager JP
    Clin Pharmacol Ther; 1976 Sep; 20(3):310-4. PubMed ID: 182429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia.
    Grundy SM; Mok HY
    J Lab Clin Med; 1977 Feb; 89(2):354-66. PubMed ID: 833472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.
    Kuo PT; Hayase K; Kostis JB; Moreyra AE
    Circulation; 1979 Feb; 59(2):199-211. PubMed ID: 215338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long term treatment of familial hypercholesterolemia with Colestipol, a new anionic exchange resin (author's transl)].
    Briani G; Fellin R; Balestrieri P; Baggio G; Baiocchi MR; Crepaldi G
    G Ital Cardiol; 1975; 5(3):390-404. PubMed ID: 1149965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of colestipol or cholestyramine on serum cholesterol and triglycerides in a long-term controlled study.
    Ryan JR; Jain A
    J Clin Pharmacol New Drugs; 1972 Jul; 12(7):268-73. PubMed ID: 4557535
    [No Abstract]   [Full Text] [Related]  

  • 29. Differences among hyperlipoproteinaemic subjects in the response of lipoprotein lipids to resin therapy.
    Miller NE; Nestel PJ
    Eur J Clin Invest; 1975 Jun; 5(3):241-7. PubMed ID: 1149783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
    Illingworth DR
    Ann Intern Med; 1984 Nov; 101(5):598-604. PubMed ID: 6567462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.
    Valeri A; Gelfand J; Blum C; Appel GB
    Am J Kidney Dis; 1986 Dec; 8(6):388-96. PubMed ID: 3544820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of a microporous cholestyramine analogue (filicol) and gemfibrozil for treatment of severe primary hypercholesterolemia. Short- and long-term results.
    Ros E; Zambón D; Bertomeu A; Cusó E; Sanllehy C; Casals E
    Arch Intern Med; 1991 Feb; 151(2):301-5. PubMed ID: 1992957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease.
    Kuo PT; Wilson AC; Kostis JB; Moreyra AE
    Am J Cardiol; 1986 Jun; 57(16):43H-48H. PubMed ID: 3524177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.
    Knopp RH; Walden CE; Warnick GR; Albers JJ; Ginsberg J; McGinnis BM
    Am J Med; 1987 Nov; 83(5B):75-84. PubMed ID: 3120587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The acceptability of resin therapy to patients attending a hospital lipid clinic.
    Iversen SA; Davidson D; Davidson C
    Br J Clin Pharmacol; 1995 Jul; 40(1):92-4. PubMed ID: 8527276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of cholestyramine and nicotinic acid in the treatment of familial type II hyperlipoproteinaemia.
    Mann JI; Harding PA; Turner RC; Wilkinson RH
    Br J Clin Pharmacol; 1977 Jun; 4(3):305-8. PubMed ID: 197982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triglyceride-rich lipoprotein cholesterol exceeds low-density lipoprotein cholesterol in hypertriglyceridemia patients.
    Ai M; Tanaka A; Tomie N; Ogita K; Sekine M; Numano F; Numano F
    Horm Metab Res; 2001 Oct; 33(10):612-7. PubMed ID: 11607882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, tolerance, and safety of colestipol HCL as a hypocholesterolemic agent in hyperlipidemic patients with studies of its effect on gastrointestinal absorption.
    Faruqui AM; Thurmond MS; Wenger J; Wenger NK
    J Pak Med Assoc; 1981 Nov; 31(11):241-5. PubMed ID: 6802993
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.